Company Filing History:
Years Active: 2013
Title: Jan Slouka: Innovator in Pharmaceutical Compounds
Introduction
Jan Slouka is a notable inventor based in Olomouc, Czech Republic. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that have potential therapeutic applications. His work focuses on innovative solutions for various medical conditions, showcasing his dedication to advancing healthcare.
Latest Patents
Jan Slouka holds a patent for a series of mono- and binuclear 4-arylazo-3,5-diamino-pyrazoles. This patent, titled "4-arylazo-3,5-diamino-pyrazole compounds and use thereof," describes compounds that are useful for inhibiting cyclin-dependent kinases, specifically CDK9. These compounds have a wide range of applications, including their use as antimitotic, pro-apoptotic, and anti-inflammatory drugs. They are particularly relevant in the chemotherapy of cancer, treatment of asthma, therapy for psoriasis, and addressing parasitic infections caused by fungi or protists. Additionally, they may be beneficial in treating Alzheimer's disease and serve as antineurodegenerative drugs. The compounds also have utility as intermediates in the preparation of flame-retardants, diagnostic reagents, and therapeutics, including antivirals and immunosuppressors.
Career Highlights
Jan Slouka is affiliated with Palacký University Olomouc, where he continues to engage in research and development. His academic background and ongoing work contribute to the advancement of pharmaceutical sciences. His innovative approach and dedication to research have positioned him as a key figure in his field.
Collaborations
Jan Slouka collaborates with several colleagues, including Petr Cankar and Iveta Frysova. These partnerships enhance the research efforts and broaden the scope of their work in pharmaceutical innovations.
Conclusion
Jan Slouka's contributions to the field of pharmaceuticals through his innovative compounds demonstrate his commitment to improving healthcare solutions. His work not only addresses critical medical challenges but also paves the way for future advancements in therapeutic applications.